• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Radio Pharmaceutical Market Share

    ID: MRFR/HC/1119-CR
    200 Pages
    Rahul Gotadki
    July 2025

    Radiopharmaceuticals Market Research Report By Application (Diagnosis, Therapy, Research), By Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals), By Radiopharmaceutical Class (Radioisotopes, Radiolabeled Compounds, Radiopharmaceutical Generators), By End Use (Hospitals, Diagnostic Imaging Centers, Research Institutions) and By Regional (North America, Europe, South America...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Radio Pharmaceutical Market Infographic
    Purchase Options
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Share

    Radio Pharmaceutical Market Share Analysis

    The Blue Biotechnology market, encompassing marine-based biotechnological applications, is gaining prominence with the exploration of marine resources for different modern and scientific purposes. Companies in this market are deploying diverse market share situating strategies to establish a critical traction. Companies are focusing on biodiscovery efforts, exploring marine creatures for unique bioactive mixtures and enzymes. This strategy positions them as pioneers in the identification and development of novel marine-derived items, catering to industries like pharmaceuticals, cosmetics, and agriculture. A key market situating strategy involves zeroing in on drug discovery and development from marine sources. Companies specializing in the identification and separation of bioactive mixtures from marine organic entities contribute to the pharmaceutical business' quest for innovative medications, elevating their status in the Blue Biotechnology market. Recognizing the importance of sustainable aquaculture, companies are developing bioproducts to enhance the health and efficiency of aquaculture and fisheries. This strategy lines up with the increasing demand for environmentally friendly arrangements in the seafood business, adding to market share development. Addressing environmental concerns, companies are situating themselves as leaders in bioremediation and contamination control utilizing marine biotechnology. Developing answers for mitigate the effect of toxins on marine ecosystems establishes these companies as environmentally cognizant entities, fostering positive brand perception. Companies are investing in marine genomics to understand the genetic makeup of marine life forms. This strategy enables the identification of valuable traits and genes for potential biotechnological applications. Companies at the forefront of marine genomics contribute to advancements in Blue Biotechnology. Responding to the developing demand for regular and health-focused items, companies are commercializing marine-derived nutraceuticals. Extracting bioactive compounds with potential health benefits positions these companies in the lucrative market for functional foods and dietary supplements.

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch

    Leave a Comment

    FAQs

    What is the projected growth of the Radiopharmaceutical market?

    The Radiopharmaceutical market is the expected increase in total market value of 18.52 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

    What is the size of the Radiopharmaceutical market?

    Radiopharmaceutical market size was valued at approximately 7.09 billion USD in 2024. This figure will reach 18.52 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

    What is the CAGR of the Radiopharmaceutical market?

    Radiopharmaceutical market is expected to grow at a CAGR of 9.12% between 2025 and 2035.

    How much will the Radiopharmaceutical market be worth by 2035?

    Radiopharmaceutical market is expected to be worth of 18.52 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

    How will the Radiopharmaceutical market perform over the next 10 years?

    Over the next 10 years the Radiopharmaceutical market is expected to shift from usd billion 7.09 to 18.52 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

    Which region is expected to dominate the Radiopharmaceuticals Market in 2024?

    North America is expected to dominate the market with a value of 3.06 billion USD in 2024.

    What will be the market size for the Diagnosis application segment by 2035?

    The Diagnosis application segment is expected to be valued at 4.84 billion USD by 2035.

    Which players are major competitors in the Global Radiopharmaceuticals Market?

    Key players include Bracco Imaging, Novartis, Bayer, and General Electric.

    What is the market size for the Research application segment in 2024?

    The Research application segment is anticipated to be valued at 1.14 billion USD in 2024.

    How much is the market expected to grow in the Asia Pacific region by 2035?

    The Asia Pacific region is projected to grow to 1.5 billion USD by 2035.

    Market Summary

    As per MRFR analysis, the Radiopharmaceuticals Market Size was estimated at 7.09 USD Billion in 2024. The Radiopharmaceuticals industry is projected to grow from 7.737 USD Billion in 2025 to 18.52 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.12 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The radiopharmaceuticals market is poised for substantial growth driven by technological advancements and increasing demand for personalized medicine.

    • North America remains the largest market for radiopharmaceuticals, driven by advanced healthcare infrastructure and high adoption rates.
    • Asia-Pacific is emerging as the fastest-growing region, fueled by increasing investments in healthcare and rising awareness of nuclear medicine.
    • The diagnostic segment continues to dominate the market, while therapeutic radiopharmaceuticals are experiencing rapid growth due to advancements in targeted therapies.
    • Key market drivers include the increasing incidence of cancer and a supportive regulatory framework that encourages innovation in nuclear medicine.

    Market Size & Forecast

    2024 Market Size 7.09 (USD Billion)
    2035 Market Size 18.52 (USD Billion)
    CAGR (2025 - 2035) 9.12%
    Largest Regional Market Share in 2024 North America

    Major Players

    <p>Cardinal Health (US), GE Healthcare (GB), Bayer AG (DE), Novartis AG (CH), Siemens Healthineers (DE), Elekta AB (SE), Lantheus Medical Imaging (US), Bracco Imaging S.p.A. (IT), NorthStar Medical Radioisotopes, LLC (US)</p>

    Market Trends

    The Radiopharmaceuticals Market is currently experiencing a transformative phase, driven by advancements in nuclear medicine and an increasing prevalence of chronic diseases. The integration of innovative technologies, such as artificial intelligence and machine learning, is enhancing the precision of diagnostic imaging and therapeutic applications. This evolution is not only improving patient outcomes but also streamlining the development processes for new radiopharmaceuticals. Furthermore, the growing emphasis on personalized medicine is likely to propel the demand for targeted therapies, which utilize radiopharmaceuticals to deliver treatment tailored to individual patient profiles. In addition, regulatory bodies are becoming more supportive of the Radiopharmaceuticals Market, facilitating faster approvals for new products. This trend is indicative of a broader recognition of the value that radiopharmaceuticals bring to healthcare. As research continues to uncover novel applications and benefits, the market appears poised for sustained growth. The collaboration between pharmaceutical companies and research institutions is fostering an environment ripe for innovation, potentially leading to breakthroughs that could redefine treatment paradigms in oncology and other fields. Overall, the Radiopharmaceuticals Market is on a promising trajectory, characterized by dynamic developments and a commitment to enhancing patient care.

    Technological Advancements

    The Radiopharmaceuticals Market is witnessing rapid technological advancements that enhance both diagnostic and therapeutic capabilities. Innovations in imaging techniques and radiochemistry are enabling more precise targeting of diseases, particularly in oncology. These developments are likely to improve the efficacy of treatments and reduce side effects, thereby increasing patient compliance and satisfaction.

    Personalized Medicine

    There is a growing trend towards personalized medicine within the Radiopharmaceuticals Market. Tailoring treatments to individual patient profiles allows for more effective interventions, particularly in complex diseases. This shift is expected to drive demand for radiopharmaceuticals that can be customized based on genetic and molecular characteristics, leading to improved therapeutic outcomes.

    Regulatory Support

    Regulatory bodies are increasingly supportive of the Radiopharmaceuticals Market, streamlining approval processes for new products. This trend suggests a recognition of the critical role that radiopharmaceuticals play in modern healthcare. Enhanced collaboration between industry stakeholders and regulators may lead to faster market entry for innovative therapies, ultimately benefiting patients.

    <p>The Global Radiopharmaceuticals Market is poised for substantial growth, driven by advancements in nuclear medicine and an increasing demand for targeted therapies in oncology.</p>

    U.S. Department of Energy

    Radio Pharmaceutical Market Market Drivers

    Increasing Incidence of Cancer

    The rising incidence of cancer worldwide is a primary driver for the Radiopharmaceuticals Market. As cancer cases continue to escalate, the demand for effective diagnostic and therapeutic solutions intensifies. Radiopharmaceuticals, which are pivotal in both imaging and treatment, are increasingly utilized in oncology. According to recent data, cancer is projected to affect approximately 1 in 5 individuals during their lifetime, leading to a surge in the need for advanced radiopharmaceuticals. This trend is likely to propel the market forward, as healthcare providers seek innovative solutions to enhance patient outcomes and improve survival rates. The Radiopharmaceuticals Market is thus positioned to benefit significantly from this growing patient population, as new therapies and imaging techniques are developed to address the complexities of cancer treatment.

    Supportive Regulatory Framework

    A supportive regulatory framework is crucial for the growth of the Radiopharmaceuticals Market. Regulatory bodies are increasingly recognizing the importance of radiopharmaceuticals in modern medicine, leading to streamlined approval processes for new products. This regulatory support fosters innovation and encourages investment in research and development. For instance, the introduction of expedited pathways for breakthrough therapies has enabled faster access to novel radiopharmaceuticals for patients. As a result, the market is likely to see an influx of new products that meet the evolving needs of healthcare providers and patients. The Radiopharmaceuticals Market stands to benefit from this favorable regulatory environment, which not only enhances the availability of innovative treatments but also promotes competition among manufacturers.

    Advancements in Nuclear Medicine

    Technological advancements in nuclear medicine are significantly influencing the Radiopharmaceuticals Market. Innovations in imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), have enhanced the precision of diagnostics. These advancements facilitate earlier detection of diseases, particularly cancers, which is crucial for effective treatment. The market is witnessing a shift towards more sophisticated radiopharmaceuticals that offer improved efficacy and safety profiles. Furthermore, the development of new isotopes and radiolabeling techniques is expanding the therapeutic applications of radiopharmaceuticals. As a result, the Radiopharmaceuticals Market is expected to experience robust growth, driven by the continuous evolution of nuclear medicine technologies that enhance patient care and treatment outcomes.

    Growing Demand for Targeted Therapies

    The increasing demand for targeted therapies is reshaping the Radiopharmaceuticals Market. Patients and healthcare providers are increasingly favoring treatments that offer specificity and reduced side effects. Radiopharmaceuticals, which can be designed to target specific cellular receptors or tumor markers, align well with this trend. The market is projected to grow as more targeted radiopharmaceuticals are developed, particularly in oncology and cardiology. Recent estimates suggest that the targeted therapy segment could account for a substantial portion of the overall radiopharmaceuticals market by 2026. This shift towards personalized medicine is likely to drive innovation and investment in the Radiopharmaceuticals Market, as stakeholders seek to develop novel agents that cater to the unique needs of individual patients.

    Rising Awareness and Acceptance of Nuclear Medicine

    Rising awareness and acceptance of nuclear medicine among healthcare professionals and patients are driving the Radiopharmaceuticals Market. Educational initiatives and outreach programs have significantly improved understanding of the benefits and applications of radiopharmaceuticals. As more healthcare providers recognize the value of nuclear medicine in diagnostics and treatment, the adoption of radiopharmaceuticals is likely to increase. Additionally, patient acceptance of these therapies is growing, as they become more informed about the advantages of radiopharmaceuticals in managing various health conditions. This trend is expected to contribute to the expansion of the Radiopharmaceuticals Market, as increased utilization of these therapies leads to improved patient outcomes and satisfaction.

    Market Segment Insights

    By Application: Diagnosis (Largest) vs. Therapy (Fastest-Growing)

    <p>In the Radiopharmaceuticals Market, the application segment is diverse, with Diagnosis holding the largest share. This category encompasses a broad range of imaging techniques that utilize radiopharmaceuticals, which are essential for accurate disease detection and management. Following Diagnosis, Therapy represents a rapidly expanding area within this market, highlighting the increasing reliance on targeted radiation treatments for various malignancies. Research applications also play a pivotal role, contributing to advancements in both diagnosis and therapeutic methodologies, although they hold a comparatively smaller market share. Recent trends indicate that the Therapy segment is experiencing significant growth, driven by technological advancements in radiotherapy treatments and increasing approvals for radiopharmaceuticals in various therapeutic applications. The demand for personalized medicine and precision targeting is continually pushing this segment forward. Moreover, growing collaborations between research institutions and pharmaceutical companies are fostering innovation in the Discovery and development of novel radiopharmaceutical applications across disease types, particularly cancer. This shift towards more effective treatments positions Therapy as a key player in the future of the Radiopharmaceuticals Market.</p>

    <p>Diagnosis (Dominant) vs. Research (Emerging)</p>

    <p>The Diagnosis segment in the Radiopharmaceuticals Market is characterized by its extensive use of imaging techniques, which are crucial for early detection of diseases such as cancer and cardiovascular disorders. It currently holds a dominant position due to the established role of nuclear medicine in patient management. This segment benefits from continuous innovations, including the development of new radiotracers and more efficient imaging equipment, making it integral to diagnostic processes. In contrast, Research is an emerging segment, characterized by its focus on developing novel radiopharmaceutical compounds and enhancing existing formulations. This segment is progressively gaining importance as more institutions seek to leverage radiopharmaceuticals for clinical trials and experimental therapies, thereby contributing to essential breakthroughs in medical science. While still growing, the Research segment is vital for future advancements in both diagnostics and therapeutics.</p>

    By Type: Diagnostic Radiopharmaceuticals (Largest) vs. Therapeutic Radiopharmaceuticals (Fastest-Growing)

    <p>The Radiopharmaceuticals Market is characterized by two primary segments: Diagnostic and Therapeutic Radiopharmaceuticals. Diagnostic Radiopharmaceuticals currently hold the largest share, driven by their extensive application in imaging and diagnostics. This segment benefits from technological advancements and a growing preference for minimally invasive diagnostic procedures. In contrast, Therapeutic Radiopharmaceuticals, although smaller in market share, are rapidly gaining traction due to their innovative applications in targeted cancer therapies, showcasing significant growth potential.</p>

    <p>Radiopharmaceuticals: Diagnostic (Dominant) vs. Therapeutic (Emerging)</p>

    <p>The Diagnostic Radiopharmaceuticals segment is dominant due to its established role in imaging techniques such as PET and SPECT, widely used in clinical practice for disease detection. This segment is characterized by a variety of agents tailored for specific imaging needs, making it indispensable in modern medical procedures. On the other hand, Therapeutic Radiopharmaceuticals are emerging as an innovative force in treatment protocols. They offer targeted therapy options that minimize collateral damage to healthy tissues, proving advantageous in oncology. The shift towards personalized medicine and increasing clinical trials in radiotherapy are leading this segment to expand rapidly, positioning it as a vital player in the evolving landscape of healthcare.</p>

    By Radiopharmaceutical Class: Radioisotopes (Largest) vs. Radiolabeled Compounds (Fastest-Growing)

    <p>The radiopharmaceutical class segment exhibits a distinct distribution in market share among various factors. Radioisotopes hold the largest share, leading the market due to their prominent role in diagnostics and therapeutic applications. Radiolabeled compounds, while relatively smaller in share, are quickly gaining traction and evolving into an increasingly significant part of this market, driven by technological advancements and increasing clinical demand.</p>

    <p>Radioisotopes (Dominant) vs. Radiolabeled Compounds (Emerging)</p>

    <p>Radioisotopes dominate the radiopharmaceutical market due to their established applications in both therapeutic and diagnostic modalities, particularly in oncology and cardiology. Their stability and effectiveness make them indispensable in medical imaging and therapy. Conversely, radiolabeled compounds are emerging as a vital component of precision medicine, offering innovative approaches to targeted therapy and personalized treatment options. The rapid advancement in radiolabeling techniques and increased research in this area are propelling the growth of radiolabeled compounds, as they provide unique solutions that enhance patient outcomes through enhanced specificity and reduced side effects.</p>

    By End Use: Hospitals (Largest) vs. Diagnostic Imaging Centers (Fastest-Growing)

    <p>In the Radiopharmaceuticals Market, hospitals are the largest end-use segment, capturing a significant portion of market share due to their comprehensive diagnostic and therapeutic capabilities. Diagnostic imaging centers follow closely behind, reflecting a notable shift in healthcare settings where targeted imaging approaches are favored, leading to enhanced patient outcomes and increased adoption of radiopharmaceutical products. Research institutions also play a vital role but have a smaller share as they primarily focus on clinical trials and innovative therapeutic developments, contributing to the overall advancement of radiopharmaceuticals.</p>

    <p>Hospitals (Dominant) vs. Research Institutions (Emerging)</p>

    <p>Hospitals are the dominant players in the radiopharmaceuticals market, leveraging their extensive infrastructure and trained personnel to administer complex radioisotope therapies. Their large-scale operations and the integration of radiopharmaceuticals into both diagnostic and treatment protocols establish a solid foundation for their market presence. On the other hand, research institutions serve as emerging agents of change within the sector, driving innovation through clinical research and trial programs. While they may not command the same market share as hospitals, their contributions to the development of novel radiopharmaceutical applications and therapies position them as essential partners in advancing the field.</p>

    Get more detailed insights about Radiopharmaceuticals Market Research Report - Forecast to 2035

    Regional Insights

    North America : Market Leader in Innovation

    North America is the largest market for radiopharmaceuticals, accounting for approximately 45% of the global share. The growth is driven by increasing cancer prevalence, advancements in nuclear medicine, and supportive regulatory frameworks. The U.S. Food and Drug Administration (FDA) plays a crucial role in expediting the approval of new radiopharmaceuticals, enhancing market dynamics. The region's robust healthcare infrastructure and high investment in research and development further bolster demand. The United States leads the North American market, with significant contributions from Canada. Key players such as Cardinal Health, GE Healthcare, and Lantheus Medical Imaging dominate the landscape, focusing on innovative solutions and strategic partnerships. The competitive environment is characterized by continuous advancements in technology and a strong emphasis on patient-centric approaches, ensuring a steady growth trajectory for the radiopharmaceuticals market in this region.

    Europe : Emerging Market with Potential

    Europe is witnessing significant growth in the radiopharmaceuticals market, holding approximately 30% of the global share. The increasing incidence of chronic diseases, coupled with advancements in imaging technologies, is driving demand. Regulatory bodies like the European Medicines Agency (EMA) are actively facilitating the approval process for new radiopharmaceuticals, which is expected to further enhance market growth. The region's focus on personalized medicine and innovative therapies is also a key growth driver. Leading countries in Europe include Germany, France, and the United Kingdom, which are home to several key players such as Bayer AG and Siemens Healthineers. The competitive landscape is marked by collaborations between pharmaceutical companies and research institutions, fostering innovation. The presence of established manufacturers and a growing number of startups in the radiopharmaceuticals sector contribute to a dynamic market environment, positioning Europe as a significant player in the global landscape.

    Asia-Pacific : Rapidly Growing Market

    Asia-Pacific is emerging as a rapidly growing market for radiopharmaceuticals, accounting for approximately 20% of the global share. The growth is driven by rising healthcare expenditures, increasing awareness of nuclear medicine, and a growing aging population. Countries like China and India are witnessing a surge in demand for advanced diagnostic and therapeutic solutions, supported by favorable government initiatives and investments in healthcare infrastructure. Regulatory bodies are also streamlining approval processes to facilitate market entry for new products. China and Japan are the leading countries in this region, with significant contributions from Australia and India. The competitive landscape is characterized by the presence of both multinational corporations and local players, such as Bracco Imaging and NorthStar Medical Radioisotopes. The focus on research and development, along with strategic collaborations, is expected to drive innovation and enhance the availability of radiopharmaceuticals in the Asia-Pacific market, making it a key area for future growth.

    Middle East and Africa : Emerging Opportunities Ahead

    The Middle East and Africa region is gradually emerging in the radiopharmaceuticals market, holding approximately 5% of the global share. The growth is primarily driven by increasing investments in healthcare infrastructure, rising awareness of nuclear medicine, and a growing prevalence of chronic diseases. Countries like South Africa and the UAE are focusing on enhancing their healthcare systems, which is expected to create new opportunities for radiopharmaceuticals. Regulatory bodies are also working towards establishing frameworks to support market growth. South Africa and the UAE are the leading markets in this region, with a growing number of healthcare facilities adopting advanced diagnostic technologies. The competitive landscape is evolving, with both local and international players entering the market. Companies are focusing on partnerships and collaborations to enhance their product offerings and expand their market reach, positioning the Middle East and Africa as a region with significant growth potential in the radiopharmaceuticals sector.

    Key Players and Competitive Insights

    The Radiopharmaceuticals Market is characterized by a dynamic competitive landscape, driven by advancements in medical imaging and targeted therapies. Key players such as Cardinal Health (US), GE Healthcare (GB), and Bayer AG (DE) are at the forefront, each adopting distinct strategies to enhance their market presence. Cardinal Health (US) focuses on expanding its product portfolio through strategic partnerships and acquisitions, while GE Healthcare (GB) emphasizes innovation in imaging technologies, particularly in PET and SPECT applications. Bayer AG (DE) is leveraging its strong research capabilities to develop novel radiopharmaceuticals, thereby positioning itself as a leader in therapeutic applications. Collectively, these strategies contribute to a competitive environment that is increasingly shaped by technological advancements and collaborative efforts.

    In terms of business tactics, companies are increasingly localizing manufacturing to reduce supply chain vulnerabilities and enhance responsiveness to regional market demands. The competitive structure of the Radiopharmaceuticals Market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they often set industry standards and drive innovation through their extensive research and development initiatives.

    In August 2025, Lantheus Medical Imaging (US) announced the launch of a new radiopharmaceutical aimed at improving diagnostic accuracy in oncology. This strategic move is significant as it not only enhances Lantheus's product offerings but also reinforces its commitment to addressing unmet clinical needs in cancer diagnostics. The introduction of this product is likely to strengthen its competitive position in a market that increasingly values precision medicine.

    In September 2025, Siemens Healthineers (DE) unveiled a partnership with a leading biotechnology firm to co-develop advanced radiopharmaceuticals for personalized therapy. This collaboration is indicative of a broader trend towards integrating biotechnology with radiopharmaceutical development, potentially leading to more effective treatment options. Such strategic alliances may enhance Siemens's capabilities in delivering innovative solutions that align with the growing demand for personalized medicine.

    In October 2025, NorthStar Medical Radioisotopes, LLC (US) expanded its production capacity by investing in a new facility dedicated to the manufacturing of medical isotopes. This expansion is crucial as it addresses the increasing global demand for radiopharmaceuticals, particularly in diagnostic imaging. By enhancing its production capabilities, NorthStar is likely to improve its market position and ensure a reliable supply of critical isotopes to healthcare providers.

    As of October 2025, the Radiopharmaceuticals Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in product development and manufacturing processes. Strategic alliances are becoming increasingly vital, as they enable companies to pool resources and expertise, thereby accelerating innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from traditional price-based competition towards a focus on technological innovation, supply chain reliability, and the development of advanced therapeutic solutions.

    Key Companies in the Radio Pharmaceutical Market market include

    Industry Developments

    The Radiopharmaceuticals Market has witnessed several significant developments recently.

    In January 2024, Novartis obtained FDA approval for the commercial production of Pluvicto at its new radioligand manufacturing facility in Indianapolis, Indiana.

    In February 2024, Bristol-Myers Squibb finalized its $4.1 billion acquisition of RayzeBio, which bolstered its actinium-based radiopharmaceutical pipeline.

    AstraZeneca acquired Fusion Pharmaceuticals for $2.4 billion in March 2024, thereby acquiring access to its FPI-2265 prostate cancer radioconjugate and manufacturing assets.

    Future Outlook

    Radio Pharmaceutical Market Future Outlook

    <p>The Radiopharmaceuticals Market is projected to grow at a 9.12% CAGR from 2024 to 2035, driven by advancements in diagnostic imaging and targeted therapies.</p>

    New opportunities lie in:

    • <p>Expansion of theranostic applications in oncology</p>
    • <p>Development of novel radiotracers for neurodegenerative diseases</p>
    • <p>Investment in automated radiopharmaceutical production facilities</p>

    <p>By 2035, the Radiopharmaceuticals Market is poised for robust growth, reflecting its critical role in modern healthcare.</p>

    Market Segmentation

    Radio Pharmaceutical Market Type Outlook

    • Diagnostic Radiopharmaceuticals
    • Therapeutic Radiopharmaceuticals

    Radio Pharmaceutical Market End Use Outlook

    • Hospitals
    • Diagnostic Imaging Centers
    • Research Institutions

    Radio Pharmaceutical Market Application Outlook

    • Diagnosis
    • Therapy
    • Research

    Radio Pharmaceutical Market Radiopharmaceutical Class Outlook

    • Radioisotopes
    • Radiolabeled Compounds
    • Radiopharmaceutical Generators

    Report Scope

    MARKET SIZE 20247.09(USD Billion)
    MARKET SIZE 20257.737(USD Billion)
    MARKET SIZE 203518.52(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)9.12% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in targeted therapies and personalized medicine drive growth in the Radiopharmaceuticals Market.
    Key Market DynamicsTechnological advancements and regulatory changes drive innovation and competition in the radiopharmaceuticals market.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    FAQs

    What is the projected growth of the Radiopharmaceutical market?

    The Radiopharmaceutical market is the expected increase in total market value of 18.52 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

    What is the size of the Radiopharmaceutical market?

    Radiopharmaceutical market size was valued at approximately 7.09 billion USD in 2024. This figure will reach 18.52 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

    What is the CAGR of the Radiopharmaceutical market?

    Radiopharmaceutical market is expected to grow at a CAGR of 9.12% between 2025 and 2035.

    How much will the Radiopharmaceutical market be worth by 2035?

    Radiopharmaceutical market is expected to be worth of 18.52 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

    How will the Radiopharmaceutical market perform over the next 10 years?

    Over the next 10 years the Radiopharmaceutical market is expected to shift from usd billion 7.09 to 18.52 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

    Which region is expected to dominate the Radiopharmaceuticals Market in 2024?

    North America is expected to dominate the market with a value of 3.06 billion USD in 2024.

    What will be the market size for the Diagnosis application segment by 2035?

    The Diagnosis application segment is expected to be valued at 4.84 billion USD by 2035.

    Which players are major competitors in the Global Radiopharmaceuticals Market?

    Key players include Bracco Imaging, Novartis, Bayer, and General Electric.

    What is the market size for the Research application segment in 2024?

    The Research application segment is anticipated to be valued at 1.14 billion USD in 2024.

    How much is the market expected to grow in the Asia Pacific region by 2035?

    The Asia Pacific region is projected to grow to 1.5 billion USD by 2035.

    1. EXECUTIVE SUMMARY
      1. Market Overview
      2. Key Findings
      3. Market Segmentation
      4. Competitive Landscape
      5. Challenges and Opportunities
      6. Future Outlook
      7. \r\n
    2. MARKET INTRODUCTION
      1. Definition
      2. Scope of the study
        1. Research Objective
        2. Assumption
        3. Limitations
    3. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
        1. Primary Interviews and Information Gathering Process
        2. Breakdown of Primary Respondents
      5. Forecasting Model
      6. Market Size Estimation
        1. Bottom-Up Approach
        2. Top-Down Approach
      7. Data Triangulation
      8. Validation
      9. \r\n
    4. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    5. MARKET FACTOR ANALYSIS
      1. Value chain Analysis
      2. Porter's Five Forces Analysis
        1. Bargaining Power of Suppliers
        2. Bargaining Power of Buyers
        3. Threat of New Entrants
        4. Threat of Substitutes
        5. Intensity of Rivalry
      3. COVID-19 Impact Analysis
        1. Market Impact Analysis
        2. Regional Impact
        3. Opportunity and Threat Analysis
      4. \r\n
    6. RADIOPHARMACEUTICALS MARKET, BY APPLICATION (USD BILLION)
      1. Diagnosis
      2. Therapy
      3. Research
    7. RADIOPHARMACEUTICALS MARKET, BY TYPE (USD BILLION)
      1. Diagnostic Radiopharmaceuticals
      2. Therapeutic Radiopharmaceuticals
    8. RADIOPHARMACEUTICALS MARKET, BY RADIOPHARMACEUTICAL CLASS (USD BILLION)
      1. Radioisotopes
      2. Radiolabeled Compounds
      3. Radiopharmaceutical Generators
    9. RADIOPHARMACEUTICALS MARKET, BY END USE (USD BILLION)
      1. Hospitals
      2. Diagnostic Imaging Centers
      3. Research Institutions
    10. RADIOPHARMACEUTICALS MARKET, BY REGIONAL (USD BILLION)
      1. North America
        1. US
        2. Canada
      2. Europe
        1. Germany
        2. UK
        3. France
        4. Russia
        5. Italy
        6. Spain
        7. Rest of Europe
      3. APAC
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Malaysia
        6. Thailand
        7. Indonesia
        8. Rest of APAC
      4. South America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of South America
      5. MEA
        1. GCC Countries
        2. South Africa
        3. Rest of MEA
      6. \r\n
    11. COMPETITIVE LANDSCAPE
      1. Overview
      2. Competitive Analysis
      3. Market share Analysis
      4. Major Growth Strategy in the Radiopharmaceuticals Market
      5. Competitive Benchmarking
      6. Leading Players in Terms of Number of Developments in the Radiopharmaceuticals Market
      7. Key developments and growth strategies
        1. New Product Launch/Service Deployment
        2. Merger & Acquisitions
        3. Joint Ventures
      8. Major Players Financial Matrix
        1. Sales and Operating Income
        2. Major Players R&D Expenditure. 2023
    12. COMPANY PROFILES
      1. Bracco Imaging
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      2. Novartis
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      3. Bayer
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      4. General Electric
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      5. Draximage
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      6. Actinium Pharmaceuticals
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      7. Lantheus Medical Imaging
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      8. Siemens Healthineers
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      9. Elekta
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      10. NorthStar Medical Radioisotopes
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      11. Ion Beam Applications
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      12. Cardinal Health
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      13. TheraSource
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      14. BristolMyers Squibb
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
      15. AbbVie
        1. Financial Overview
        2. Products Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategies
    13. APPENDIX
      1. References
      2. Related Reports
    14. LIST OF TABLES
      1. \r\n
    15. LIST OF ASSUMPTIONS
    16. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    17. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    18. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    19. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    20. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    21. US RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    22. US RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    23. US RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    24. US RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    25. US RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    26. CANADA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    27. CANADA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    28. CANADA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    29. CANADA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    30. CANADA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    31. EUROPE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    32. EUROPE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    33. EUROPE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    34. EUROPE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    35. EUROPE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    36. GERMANY RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    37. GERMANY RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    38. GERMANY RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    39. GERMANY RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    40. GERMANY RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    41. UK RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    42. UK RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    43. UK RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    44. UK RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    45. UK RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    46. FRANCE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    47. FRANCE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    48. FRANCE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    49. FRANCE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    50. FRANCE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    51. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    52. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    53. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    54. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    55. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    56. ITALY RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    57. ITALY RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    58. ITALY RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    59. ITALY RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    60. ITALY RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    61. SPAIN RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    62. SPAIN RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    63. SPAIN RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    64. SPAIN RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    65. SPAIN RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    66. REST OF EUROPE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    67. REST OF EUROPE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    68. REST OF EUROPE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    69. REST OF EUROPE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    70. REST OF EUROPE RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    71. APAC RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    72. APAC RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    73. APAC RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    74. APAC RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    75. APAC RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    76. CHINA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    77. CHINA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    78. CHINA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    79. CHINA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    80. CHINA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    81. INDIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    82. INDIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    83. INDIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    84. INDIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    85. INDIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    86. JAPAN RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    87. JAPAN RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    88. JAPAN RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    89. JAPAN RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    90. JAPAN RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    91. SOUTH KOREA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    92. SOUTH KOREA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    93. SOUTH KOREA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    94. SOUTH KOREA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    95. SOUTH KOREA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    96. MALAYSIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    97. MALAYSIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    98. MALAYSIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    99. MALAYSIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    100. MALAYSIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    101. THAILAND RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    102. THAILAND RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    103. THAILAND RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    104. THAILAND RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    105. THAILAND RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    106. INDONESIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    107. INDONESIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    108. INDONESIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    109. INDONESIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    110. INDONESIA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    111. REST OF APAC RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    112. REST OF APAC RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    113. REST OF APAC RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    114. REST OF APAC RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    115. REST OF APAC RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    116. SOUTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    117. SOUTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    118. SOUTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    119. SOUTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    120. SOUTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    121. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    122. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    123. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    124. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    125. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    126. MEXICO RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    127. MEXICO RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    128. MEXICO RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    129. MEXICO RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    130. MEXICO RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    131. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    132. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    133. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    134. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    135. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    136. REST OF SOUTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    137. REST OF SOUTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    138. REST OF SOUTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    139. REST OF SOUTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    140. REST OF SOUTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    141. MEA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    142. MEA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    143. MEA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    144. MEA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    145. MEA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    146. GCC COUNTRIES RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    147. GCC COUNTRIES RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    148. GCC COUNTRIES RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    149. GCC COUNTRIES RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    150. GCC COUNTRIES RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    151. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    152. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    153. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    154. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    155. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    156. REST OF MEA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
    157. REST OF MEA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD BILLIONS)
    158. REST OF MEA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY RADIOPHARMACEUTICAL CLASS, 2019-2035 (USD BILLIONS)
    159. REST OF MEA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
    160. REST OF MEA RADIOPHARMACEUTICALS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    161. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    162. ACQUISITION/PARTNERSHIP
      1. \r\n
      2. \r\n
      3. \r\n
      4. \r\n
      5. \r\n
      6. \r\n
      7. \r\n
      8. \r\n
      9. \r\n
      10. \r\n
      11. \r\n
      12. \r\n
      13. \r\n
      14. \r\n
      15. \r\n
    163. LIST OF FIGURES
      1. \r\n
    164. MARKET SYNOPSIS
    165. NORTH AMERICA RADIOPHARMACEUTICALS MARKET ANALYSIS
    166. US RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    167. US RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    168. US RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    169. US RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    170. US RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    171. CANADA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    172. CANADA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    173. CANADA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    174. CANADA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    175. CANADA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    176. EUROPE RADIOPHARMACEUTICALS MARKET ANALYSIS
    177. GERMANY RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    178. GERMANY RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    179. GERMANY RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    180. GERMANY RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    181. GERMANY RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    182. UK RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    183. UK RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    184. UK RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    185. UK RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    186. UK RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    187. FRANCE RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    188. FRANCE RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    189. FRANCE RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    190. FRANCE RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    191. FRANCE RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    192. RUSSIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    193. RUSSIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    194. RUSSIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    195. RUSSIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    196. RUSSIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    197. ITALY RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    198. ITALY RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    199. ITALY RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    200. ITALY RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    201. ITALY RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    202. SPAIN RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    203. SPAIN RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    204. SPAIN RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    205. SPAIN RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    206. SPAIN RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    207. REST OF EUROPE RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    208. REST OF EUROPE RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    209. REST OF EUROPE RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    210. REST OF EUROPE RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    211. REST OF EUROPE RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    212. APAC RADIOPHARMACEUTICALS MARKET ANALYSIS
    213. CHINA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    214. CHINA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    215. CHINA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    216. CHINA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    217. CHINA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    218. INDIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    219. INDIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    220. INDIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    221. INDIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    222. INDIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    223. JAPAN RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    224. JAPAN RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    225. JAPAN RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    226. JAPAN RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    227. JAPAN RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    228. SOUTH KOREA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    229. SOUTH KOREA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    230. SOUTH KOREA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    231. SOUTH KOREA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    232. SOUTH KOREA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    233. MALAYSIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    234. MALAYSIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    235. MALAYSIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    236. MALAYSIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    237. MALAYSIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    238. THAILAND RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    239. THAILAND RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    240. THAILAND RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    241. THAILAND RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    242. THAILAND RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    243. INDONESIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    244. INDONESIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    245. INDONESIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    246. INDONESIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    247. INDONESIA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    248. REST OF APAC RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    249. REST OF APAC RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    250. REST OF APAC RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    251. REST OF APAC RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    252. REST OF APAC RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    253. SOUTH AMERICA RADIOPHARMACEUTICALS MARKET ANALYSIS
    254. BRAZIL RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    255. BRAZIL RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    256. BRAZIL RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    257. BRAZIL RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    258. BRAZIL RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    259. MEXICO RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    260. MEXICO RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    261. MEXICO RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    262. MEXICO RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    263. MEXICO RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    264. ARGENTINA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    265. ARGENTINA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    266. ARGENTINA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    267. ARGENTINA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    268. ARGENTINA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    269. REST OF SOUTH AMERICA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    270. REST OF SOUTH AMERICA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    271. REST OF SOUTH AMERICA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    272. REST OF SOUTH AMERICA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    273. REST OF SOUTH AMERICA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    274. MEA RADIOPHARMACEUTICALS MARKET ANALYSIS
    275. GCC COUNTRIES RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    276. GCC COUNTRIES RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    277. GCC COUNTRIES RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    278. GCC COUNTRIES RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    279. GCC COUNTRIES RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    280. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    281. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    282. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    283. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    284. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    285. REST OF MEA RADIOPHARMACEUTICALS MARKET ANALYSIS BY APPLICATION
    286. REST OF MEA RADIOPHARMACEUTICALS MARKET ANALYSIS BY TYPE
    287. REST OF MEA RADIOPHARMACEUTICALS MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS
    288. REST OF MEA RADIOPHARMACEUTICALS MARKET ANALYSIS BY END USE
    289. REST OF MEA RADIOPHARMACEUTICALS MARKET ANALYSIS BY REGIONAL
    290. KEY BUYING CRITERIA OF RADIOPHARMACEUTICALS MARKET
    291. RESEARCH PROCESS OF MRFR
    292. DRO ANALYSIS OF RADIOPHARMACEUTICALS MARKET
    293. DRIVERS IMPACT ANALYSIS: RADIOPHARMACEUTICALS MARKET
    294. RESTRAINTS IMPACT ANALYSIS: RADIOPHARMACEUTICALS MARKET
    295. SUPPLY / VALUE CHAIN: RADIOPHARMACEUTICALS MARKET
    296. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2025 (% SHARE)
    297. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019 TO 2035 (USD Billions)
    298. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2025 (% SHARE)
    299. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019 TO 2035 (USD Billions)
    300. RADIOPHARMACEUTICALS MARKET, BY RADIOPHARMACEUTICAL CLASS, 2025 (% SHARE)
    301. RADIOPHARMACEUTICALS MARKET, BY RADIOPHARMACEUTICAL CLASS, 2019 TO 2035 (USD Billions)
    302. RADIOPHARMACEUTICALS MARKET, BY END USE, 2025 (% SHARE)
    303. RADIOPHARMACEUTICALS MARKET, BY END USE, 2019 TO 2035 (USD Billions)
    304. RADIOPHARMACEUTICALS MARKET, BY REGIONAL, 2025 (% SHARE)
    305. RADIOPHARMACEUTICALS MARKET, BY REGIONAL, 2019 TO 2035 (USD Billions)
    306. BENCHMARKING OF MAJOR COMPETITORS
      1. "

    Radiopharmaceuticals Market Segmentation

    • Radiopharmaceuticals Market By Application (USD Billion, 2019-2035)
      • Diagnosis
      • Therapy
      • Research
    • Radiopharmaceuticals Market By Type (USD Billion, 2019-2035)
      • Diagnostic Radiopharmaceuticals
      • Therapeutic Radiopharmaceuticals
    • Radiopharmaceuticals Market By Radiopharmaceutical Class (USD Billion, 2019-2035)
      • Radioisotopes
      • Radiolabeled Compounds
      • Radiopharmaceutical Generators
    • Radiopharmaceuticals Market By End Use (USD Billion, 2019-2035)
      • Hospitals
      • Diagnostic Imaging Centers
      • Research Institutions
    • Radiopharmaceuticals Market By Regional (USD Billion, 2019-2035)
      • North America
      • Europe
      • South America
      • Asia Pacific
      • Middle East and Africa

    Radiopharmaceuticals Market Regional Outlook (USD Billion, 2019-2035)

    • North America Outlook (USD Billion, 2019-2035)
      • North America Radiopharmaceuticals Market by Application Type
        • Diagnosis
        • Therapy
        • Research
      • North America Radiopharmaceuticals Market by Type
        • Diagnostic Radiopharmaceuticals
        • Therapeutic Radiopharmaceuticals
      • North America Radiopharmaceuticals Market by Radiopharmaceutical Class Type
        • Radioisotopes
        • Radiolabeled Compounds
        • Radiopharmaceutical Generators
      • North America Radiopharmaceuticals Market by End Use Type
        • Hospitals
        • Diagnostic Imaging Centers
        • Research Institutions
      • North America Radiopharmaceuticals Market by Regional Type
        • US
        • Canada
      • US Outlook (USD Billion, 2019-2035)
      • US Radiopharmaceuticals Market by Application Type
        • Diagnosis
        • Therapy
        • Research
      • US Radiopharmaceuticals Market by Type
        • Diagnostic Radiopharmaceuticals
        • Therapeutic Radiopharmaceuticals
      • US Radiopharmaceuticals Market by Radiopharmaceutical Class Type
        • Radioisotopes
        • Radiolabeled Compounds
        • Radiopharmaceutical Generators
      • US Radiopharmaceuticals Market by End Use Type
        • Hospitals
        • Diagnostic Imaging Centers
        • Research Institutions
      • CANADA Outlook (USD Billion, 2019-2035)
      • CANADA Radiopharmaceuticals Market by Application Type
        • Diagnosis
        • Therapy
        • Research
      • CANADA Radiopharmaceuticals Market by Type
        • Diagnostic Radiopharmaceuticals
        • Therapeutic Radiopharmaceuticals
      • CANADA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
        • Radioisotopes
        • Radiolabeled Compounds
        • Radiopharmaceutical Generators
      • CANADA Radiopharmaceuticals Market by End Use Type
        • Hospitals
        • Diagnostic Imaging Centers
        • Research Institutions
      • Europe Outlook (USD Billion, 2019-2035)
        • Europe Radiopharmaceuticals Market by Application Type
          • Diagnosis
          • Therapy
          • Research
        • Europe Radiopharmaceuticals Market by Type
          • Diagnostic Radiopharmaceuticals
          • Therapeutic Radiopharmaceuticals
        • Europe Radiopharmaceuticals Market by Radiopharmaceutical Class Type
          • Radioisotopes
          • Radiolabeled Compounds
          • Radiopharmaceutical Generators
        • Europe Radiopharmaceuticals Market by End Use Type
          • Hospitals
          • Diagnostic Imaging Centers
          • Research Institutions
        • Europe Radiopharmaceuticals Market by Regional Type
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Spain
          • Rest of Europe
        • GERMANY Outlook (USD Billion, 2019-2035)
        • GERMANY Radiopharmaceuticals Market by Application Type
          • Diagnosis
          • Therapy
          • Research
        • GERMANY Radiopharmaceuticals Market by Type
          • Diagnostic Radiopharmaceuticals
          • Therapeutic Radiopharmaceuticals
        • GERMANY Radiopharmaceuticals Market by Radiopharmaceutical Class Type
          • Radioisotopes
          • Radiolabeled Compounds
          • Radiopharmaceutical Generators
        • GERMANY Radiopharmaceuticals Market by End Use Type
          • Hospitals
          • Diagnostic Imaging Centers
          • Research Institutions
        • UK Outlook (USD Billion, 2019-2035)
        • UK Radiopharmaceuticals Market by Application Type
          • Diagnosis
          • Therapy
          • Research
        • UK Radiopharmaceuticals Market by Type
          • Diagnostic Radiopharmaceuticals
          • Therapeutic Radiopharmaceuticals
        • UK Radiopharmaceuticals Market by Radiopharmaceutical Class Type
          • Radioisotopes
          • Radiolabeled Compounds
          • Radiopharmaceutical Generators
        • UK Radiopharmaceuticals Market by End Use Type
          • Hospitals
          • Diagnostic Imaging Centers
          • Research Institutions
        • FRANCE Outlook (USD Billion, 2019-2035)
        • FRANCE Radiopharmaceuticals Market by Application Type
          • Diagnosis
          • Therapy
          • Research
        • FRANCE Radiopharmaceuticals Market by Type
          • Diagnostic Radiopharmaceuticals
          • Therapeutic Radiopharmaceuticals
        • FRANCE Radiopharmaceuticals Market by Radiopharmaceutical Class Type
          • Radioisotopes
          • Radiolabeled Compounds
          • Radiopharmaceutical Generators
        • FRANCE Radiopharmaceuticals Market by End Use Type
          • Hospitals
          • Diagnostic Imaging Centers
          • Research Institutions
        • RUSSIA Outlook (USD Billion, 2019-2035)
        • RUSSIA Radiopharmaceuticals Market by Application Type
          • Diagnosis
          • Therapy
          • Research
        • RUSSIA Radiopharmaceuticals Market by Type
          • Diagnostic Radiopharmaceuticals
          • Therapeutic Radiopharmaceuticals
        • RUSSIA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
          • Radioisotopes
          • Radiolabeled Compounds
          • Radiopharmaceutical Generators
        • RUSSIA Radiopharmaceuticals Market by End Use Type
          • Hospitals
          • Diagnostic Imaging Centers
          • Research Institutions
        • ITALY Outlook (USD Billion, 2019-2035)
        • ITALY Radiopharmaceuticals Market by Application Type
          • Diagnosis
          • Therapy
          • Research
        • ITALY Radiopharmaceuticals Market by Type
          • Diagnostic Radiopharmaceuticals
          • Therapeutic Radiopharmaceuticals
        • ITALY Radiopharmaceuticals Market by Radiopharmaceutical Class Type
          • Radioisotopes
          • Radiolabeled Compounds
          • Radiopharmaceutical Generators
        • ITALY Radiopharmaceuticals Market by End Use Type
          • Hospitals
          • Diagnostic Imaging Centers
          • Research Institutions
        • SPAIN Outlook (USD Billion, 2019-2035)
        • SPAIN Radiopharmaceuticals Market by Application Type
          • Diagnosis
          • Therapy
          • Research
        • SPAIN Radiopharmaceuticals Market by Type
          • Diagnostic Radiopharmaceuticals
          • Therapeutic Radiopharmaceuticals
        • SPAIN Radiopharmaceuticals Market by Radiopharmaceutical Class Type
          • Radioisotopes
          • Radiolabeled Compounds
          • Radiopharmaceutical Generators
        • SPAIN Radiopharmaceuticals Market by End Use Type
          • Hospitals
          • Diagnostic Imaging Centers
          • Research Institutions
        • REST OF EUROPE Outlook (USD Billion, 2019-2035)
        • REST OF EUROPE Radiopharmaceuticals Market by Application Type
          • Diagnosis
          • Therapy
          • Research
        • REST OF EUROPE Radiopharmaceuticals Market by Type
          • Diagnostic Radiopharmaceuticals
          • Therapeutic Radiopharmaceuticals
        • REST OF EUROPE Radiopharmaceuticals Market by Radiopharmaceutical Class Type
          • Radioisotopes
          • Radiolabeled Compounds
          • Radiopharmaceutical Generators
        • REST OF EUROPE Radiopharmaceuticals Market by End Use Type
          • Hospitals
          • Diagnostic Imaging Centers
          • Research Institutions
        • APAC Outlook (USD Billion, 2019-2035)
          • APAC Radiopharmaceuticals Market by Application Type
            • Diagnosis
            • Therapy
            • Research
          • APAC Radiopharmaceuticals Market by Type
            • Diagnostic Radiopharmaceuticals
            • Therapeutic Radiopharmaceuticals
          • APAC Radiopharmaceuticals Market by Radiopharmaceutical Class Type
            • Radioisotopes
            • Radiolabeled Compounds
            • Radiopharmaceutical Generators
          • APAC Radiopharmaceuticals Market by End Use Type
            • Hospitals
            • Diagnostic Imaging Centers
            • Research Institutions
          • APAC Radiopharmaceuticals Market by Regional Type
            • China
            • India
            • Japan
            • South Korea
            • Malaysia
            • Thailand
            • Indonesia
            • Rest of APAC
          • CHINA Outlook (USD Billion, 2019-2035)
          • CHINA Radiopharmaceuticals Market by Application Type
            • Diagnosis
            • Therapy
            • Research
          • CHINA Radiopharmaceuticals Market by Type
            • Diagnostic Radiopharmaceuticals
            • Therapeutic Radiopharmaceuticals
          • CHINA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
            • Radioisotopes
            • Radiolabeled Compounds
            • Radiopharmaceutical Generators
          • CHINA Radiopharmaceuticals Market by End Use Type
            • Hospitals
            • Diagnostic Imaging Centers
            • Research Institutions
          • INDIA Outlook (USD Billion, 2019-2035)
          • INDIA Radiopharmaceuticals Market by Application Type
            • Diagnosis
            • Therapy
            • Research
          • INDIA Radiopharmaceuticals Market by Type
            • Diagnostic Radiopharmaceuticals
            • Therapeutic Radiopharmaceuticals
          • INDIA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
            • Radioisotopes
            • Radiolabeled Compounds
            • Radiopharmaceutical Generators
          • INDIA Radiopharmaceuticals Market by End Use Type
            • Hospitals
            • Diagnostic Imaging Centers
            • Research Institutions
          • JAPAN Outlook (USD Billion, 2019-2035)
          • JAPAN Radiopharmaceuticals Market by Application Type
            • Diagnosis
            • Therapy
            • Research
          • JAPAN Radiopharmaceuticals Market by Type
            • Diagnostic Radiopharmaceuticals
            • Therapeutic Radiopharmaceuticals
          • JAPAN Radiopharmaceuticals Market by Radiopharmaceutical Class Type
            • Radioisotopes
            • Radiolabeled Compounds
            • Radiopharmaceutical Generators
          • JAPAN Radiopharmaceuticals Market by End Use Type
            • Hospitals
            • Diagnostic Imaging Centers
            • Research Institutions
          • SOUTH KOREA Outlook (USD Billion, 2019-2035)
          • SOUTH KOREA Radiopharmaceuticals Market by Application Type
            • Diagnosis
            • Therapy
            • Research
          • SOUTH KOREA Radiopharmaceuticals Market by Type
            • Diagnostic Radiopharmaceuticals
            • Therapeutic Radiopharmaceuticals
          • SOUTH KOREA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
            • Radioisotopes
            • Radiolabeled Compounds
            • Radiopharmaceutical Generators
          • SOUTH KOREA Radiopharmaceuticals Market by End Use Type
            • Hospitals
            • Diagnostic Imaging Centers
            • Research Institutions
          • MALAYSIA Outlook (USD Billion, 2019-2035)
          • MALAYSIA Radiopharmaceuticals Market by Application Type
            • Diagnosis
            • Therapy
            • Research
          • MALAYSIA Radiopharmaceuticals Market by Type
            • Diagnostic Radiopharmaceuticals
            • Therapeutic Radiopharmaceuticals
          • MALAYSIA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
            • Radioisotopes
            • Radiolabeled Compounds
            • Radiopharmaceutical Generators
          • MALAYSIA Radiopharmaceuticals Market by End Use Type
            • Hospitals
            • Diagnostic Imaging Centers
            • Research Institutions
          • THAILAND Outlook (USD Billion, 2019-2035)
          • THAILAND Radiopharmaceuticals Market by Application Type
            • Diagnosis
            • Therapy
            • Research
          • THAILAND Radiopharmaceuticals Market by Type
            • Diagnostic Radiopharmaceuticals
            • Therapeutic Radiopharmaceuticals
          • THAILAND Radiopharmaceuticals Market by Radiopharmaceutical Class Type
            • Radioisotopes
            • Radiolabeled Compounds
            • Radiopharmaceutical Generators
          • THAILAND Radiopharmaceuticals Market by End Use Type
            • Hospitals
            • Diagnostic Imaging Centers
            • Research Institutions
          • INDONESIA Outlook (USD Billion, 2019-2035)
          • INDONESIA Radiopharmaceuticals Market by Application Type
            • Diagnosis
            • Therapy
            • Research
          • INDONESIA Radiopharmaceuticals Market by Type
            • Diagnostic Radiopharmaceuticals
            • Therapeutic Radiopharmaceuticals
          • INDONESIA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
            • Radioisotopes
            • Radiolabeled Compounds
            • Radiopharmaceutical Generators
          • INDONESIA Radiopharmaceuticals Market by End Use Type
            • Hospitals
            • Diagnostic Imaging Centers
            • Research Institutions
          • REST OF APAC Outlook (USD Billion, 2019-2035)
          • REST OF APAC Radiopharmaceuticals Market by Application Type
            • Diagnosis
            • Therapy
            • Research
          • REST OF APAC Radiopharmaceuticals Market by Type
            • Diagnostic Radiopharmaceuticals
            • Therapeutic Radiopharmaceuticals
          • REST OF APAC Radiopharmaceuticals Market by Radiopharmaceutical Class Type
            • Radioisotopes
            • Radiolabeled Compounds
            • Radiopharmaceutical Generators
          • REST OF APAC Radiopharmaceuticals Market by End Use Type
            • Hospitals
            • Diagnostic Imaging Centers
            • Research Institutions
          • South America Outlook (USD Billion, 2019-2035)
            • South America Radiopharmaceuticals Market by Application Type
              • Diagnosis
              • Therapy
              • Research
            • South America Radiopharmaceuticals Market by Type
              • Diagnostic Radiopharmaceuticals
              • Therapeutic Radiopharmaceuticals
            • South America Radiopharmaceuticals Market by Radiopharmaceutical Class Type
              • Radioisotopes
              • Radiolabeled Compounds
              • Radiopharmaceutical Generators
            • South America Radiopharmaceuticals Market by End Use Type
              • Hospitals
              • Diagnostic Imaging Centers
              • Research Institutions
            • South America Radiopharmaceuticals Market by Regional Type
              • Brazil
              • Mexico
              • Argentina
              • Rest of South America
            • BRAZIL Outlook (USD Billion, 2019-2035)
            • BRAZIL Radiopharmaceuticals Market by Application Type
              • Diagnosis
              • Therapy
              • Research
            • BRAZIL Radiopharmaceuticals Market by Type
              • Diagnostic Radiopharmaceuticals
              • Therapeutic Radiopharmaceuticals
            • BRAZIL Radiopharmaceuticals Market by Radiopharmaceutical Class Type
              • Radioisotopes
              • Radiolabeled Compounds
              • Radiopharmaceutical Generators
            • BRAZIL Radiopharmaceuticals Market by End Use Type
              • Hospitals
              • Diagnostic Imaging Centers
              • Research Institutions
            • MEXICO Outlook (USD Billion, 2019-2035)
            • MEXICO Radiopharmaceuticals Market by Application Type
              • Diagnosis
              • Therapy
              • Research
            • MEXICO Radiopharmaceuticals Market by Type
              • Diagnostic Radiopharmaceuticals
              • Therapeutic Radiopharmaceuticals
            • MEXICO Radiopharmaceuticals Market by Radiopharmaceutical Class Type
              • Radioisotopes
              • Radiolabeled Compounds
              • Radiopharmaceutical Generators
            • MEXICO Radiopharmaceuticals Market by End Use Type
              • Hospitals
              • Diagnostic Imaging Centers
              • Research Institutions
            • ARGENTINA Outlook (USD Billion, 2019-2035)
            • ARGENTINA Radiopharmaceuticals Market by Application Type
              • Diagnosis
              • Therapy
              • Research
            • ARGENTINA Radiopharmaceuticals Market by Type
              • Diagnostic Radiopharmaceuticals
              • Therapeutic Radiopharmaceuticals
            • ARGENTINA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
              • Radioisotopes
              • Radiolabeled Compounds
              • Radiopharmaceutical Generators
            • ARGENTINA Radiopharmaceuticals Market by End Use Type
              • Hospitals
              • Diagnostic Imaging Centers
              • Research Institutions
            • REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2035)
            • REST OF SOUTH AMERICA Radiopharmaceuticals Market by Application Type
              • Diagnosis
              • Therapy
              • Research
            • REST OF SOUTH AMERICA Radiopharmaceuticals Market by Type
              • Diagnostic Radiopharmaceuticals
              • Therapeutic Radiopharmaceuticals
            • REST OF SOUTH AMERICA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
              • Radioisotopes
              • Radiolabeled Compounds
              • Radiopharmaceutical Generators
            • REST OF SOUTH AMERICA Radiopharmaceuticals Market by End Use Type
              • Hospitals
              • Diagnostic Imaging Centers
              • Research Institutions
            • MEA Outlook (USD Billion, 2019-2035)
              • MEA Radiopharmaceuticals Market by Application Type
                • Diagnosis
                • Therapy
                • Research
              • MEA Radiopharmaceuticals Market by Type
                • Diagnostic Radiopharmaceuticals
                • Therapeutic Radiopharmaceuticals
              • MEA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
                • Radioisotopes
                • Radiolabeled Compounds
                • Radiopharmaceutical Generators
              • MEA Radiopharmaceuticals Market by End Use Type
                • Hospitals
                • Diagnostic Imaging Centers
                • Research Institutions
              • MEA Radiopharmaceuticals Market by Regional Type
                • GCC Countries
                • South Africa
                • Rest of MEA
              • GCC COUNTRIES Outlook (USD Billion, 2019-2035)
              • GCC COUNTRIES Radiopharmaceuticals Market by Application Type
                • Diagnosis
                • Therapy
                • Research
              • GCC COUNTRIES Radiopharmaceuticals Market by Type
                • Diagnostic Radiopharmaceuticals
                • Therapeutic Radiopharmaceuticals
              • GCC COUNTRIES Radiopharmaceuticals Market by Radiopharmaceutical Class Type
                • Radioisotopes
                • Radiolabeled Compounds
                • Radiopharmaceutical Generators
              • GCC COUNTRIES Radiopharmaceuticals Market by End Use Type
                • Hospitals
                • Diagnostic Imaging Centers
                • Research Institutions
              • SOUTH AFRICA Outlook (USD Billion, 2019-2035)
              • SOUTH AFRICA Radiopharmaceuticals Market by Application Type
                • Diagnosis
                • Therapy
                • Research
              • SOUTH AFRICA Radiopharmaceuticals Market by Type
                • Diagnostic Radiopharmaceuticals
                • Therapeutic Radiopharmaceuticals
              • SOUTH AFRICA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
                • Radioisotopes
                • Radiolabeled Compounds
                • Radiopharmaceutical Generators
              • SOUTH AFRICA Radiopharmaceuticals Market by End Use Type
                • Hospitals
                • Diagnostic Imaging Centers
                • Research Institutions
              • REST OF MEA Outlook (USD Billion, 2019-2035)
              • REST OF MEA Radiopharmaceuticals Market by Application Type
                • Diagnosis
                • Therapy
                • Research
              • REST OF MEA Radiopharmaceuticals Market by Type
                • Diagnostic Radiopharmaceuticals
                • Therapeutic Radiopharmaceuticals
              • REST OF MEA Radiopharmaceuticals Market by Radiopharmaceutical Class Type
                • Radioisotopes
                • Radiolabeled Compounds
                • Radiopharmaceutical Generators
              • REST OF MEA Radiopharmaceuticals Market by End Use Type
                • Hospitals
                • Diagnostic Imaging Centers
                • Research Institutions
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization ✓ ✓ ✓
    Direct Access to Analyst ✓ ✓ ✓
    Deliverable Format ✓ ✓ ✓
    Platform Access ✗ ✗ ✓
    Discount on Next Purchase 10% 15% 15%
    Printable Versions ✗ ✗ ✓